ORTX - Orchard wins reimbursement for stem cell gene therapy in U.K.

Orchard Therapeutics (NASDAQ:ORTX) is trading ~8% higher in the pre-market on Friday after the company announced an agreement with the National Health Service (NHS) to allow access to its stem cell gene therapy Libmeldy for eligible children. Libmeldy, also known as atidarsagene autotemcel, is approved in Europe for a certain group of patients with metachromatic leukodystrophy (MLD), a rare inherited disease affecting the human metabolic system. Under the partnership, all children with MLD in England and Wales who come under the European marketing authorization for the therapy will gain access to it.  As a result, Libmeldy becomes the first-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England, the company said. After winning European approval for Libmeldy, Orchard (ORTX) has so far treated two early-onset MLD patients in Germany and France under early access arrangements for reimbursements. The negotiations for final reimbursements are currently ongoing. Read: In December, Cantor Fitzgerald

For further details see:

Orchard wins reimbursement for stem cell gene therapy in U.K.